The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Transmedics Group Inc (NASDAQ: TMDX) closed the day trading at $136.6 up 0.07% from the previous closing price of $136.51. In other words, the price has increased by $0.07 from its previous closing price. On the day, 0.64 million shares were traded. TMDX stock price reached its highest trading level at $142.95 during the session, while it also had its lowest trading level at $136.45.
Ratios:
For a better understanding of TMDX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.01 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 38.69. For the most recent quarter (mrq), Quick Ratio is recorded 7.13 and its Current Ratio is at 7.69. In the meantime, Its Debt-to-Equity ratio is 1.46 whereas as Long-Term Debt/Eq ratio is at 1.44.
On October 13, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $145.
On September 16, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $155.Evercore ISI initiated its Outperform rating on September 16, 2025, with a $155 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 03 ’25 when Weill David sold 5,000 shares for $138.64 per share. The transaction valued at 693,200 led to the insider holds 12,134 shares of the business.
Hernandez Gerardo sold 920 shares of TMDX for $128,450 on Dec 04 ’25. The Chief Financial Officer now owns 15,064 shares after completing the transaction at $139.62 per share. On Dec 03 ’25, another insider, DAVID WEILL, who serves as the Director of the company, bought 5,000 shares for $138.64 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 4668212736 and an Enterprise Value of 4718311936. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 55.18, and their Forward P/E ratio for the next fiscal year is 47.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.04. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.24 while its Price-to-Book (P/B) ratio in mrq is 13.13. Its current Enterprise Value per Revenue stands at 8.331 whereas that against EBITDA is 39.14.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.00, which has changed by 0.97869253 over the last 52 weeks, in comparison to a change of 0.13844287 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $156.00, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 9.43%, while the 200-Day Moving Average is calculated to be 23.48%.
Shares Statistics:
Over the past 3-months, TMDX traded about 962.38K shares per day on average, while over the past 10 days, TMDX traded about 840990 shares per day. A total of 34.14M shares are outstanding, with a floating share count of 33.00M. Insiders hold about 3.43% of the company’s shares, while institutions hold 110.10% stake in the company. Shares short for TMDX as of 1763078400 were 6860927 with a Short Ratio of 7.13, compared to 1760486400 on 7971237. Therefore, it implies a Short% of Shares Outstanding of 6860927 and a Short% of Float of 34.43.
Earnings Estimates
Its stock is currently analyzed by 8.0 different market analysts. The consensus estimate for the next quarter is $0.71, with high estimates of $0.79 and low estimates of $0.55.
Analysts are recommending an EPS of between $2.82 and $2.38 for the fiscal current year, implying an average EPS of $2.58. EPS for the following year is $2.96, with 9.0 analysts recommending between $3.52 and $2.47.
Revenue Estimates
10 analysts predict $156.34M in revenue for. The current quarter. It ranges from a high estimate of $160.1M to a low estimate of $155M. As of. The current estimate, Transmedics Group Inc’s year-ago sales were $121.62MFor the next quarter, 10 analysts are estimating revenue of $171.09M. There is a high estimate of $181.5M for the next quarter, whereas the lowest estimate is $163.4M.
A total of 13 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $604.8M, while the lowest revenue estimate was $599M, resulting in an average revenue estimate of $601M. In the same quarter a year ago, actual revenue was $441.54MBased on 12 analysts’ estimates, the company’s revenue will be $724.94M in the next fiscal year. The high estimate is $753.9M and the low estimate is $686.8M.
